AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference

November 4, 2019

BRISBANE, Calif.--(BUSINESS WIRE)--Nov 4, 2019--

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in a fireside chat at the Credit Suisse 28 th Annual Healthcare Conference on Tuesday, November 12, 2019 at 1:15 p.m. MST in Scottsdale, Arizona.

A live webcast of the fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. A replay will also be available following the webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies. The Company’s C haracterized O ral D esensitization I mmuno T herapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first, investigational, complex biologic product candidate, AR101, is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut. The BLA for AR101 is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency (EMA) is reviewing Aimmune’s Marketing Authorization Application (MAA) for AR101 which Aimmune submitted in June 2019. Aimmune initiated a randomized phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019. For more information, please see www.aimmune.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005852/en/

CONTACT: Investors:

DeDe Sheel

(917) 834-1494

dsheel@aimmune.com Media:

Jerica Pitts

(312) 858-3469

jpitts@w2ogroup.com

KEYWORD: CALIFORNIA ARIZONA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MANAGED CARE BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Aimmune Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/04/2019 04:05 PM/DISC: 11/04/2019 04:05 PM

http://www.businesswire.com/news/home/20191104005852/en